Bone Effects of Anti-Cancer Treatments in 2024.

IF 3.3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Calcified Tissue International Pub Date : 2025-03-27 DOI:10.1007/s00223-025-01362-0

Marie Teissonnière, Mathieu Point, Emmanuel Biver, Peyman Hadji, Edith Bonnelye, Peter R Ebeling, David Kendler, Tobias de Villiers, Gerold Holzer, Jean-Jacques Body, Ghada El Hajj Fuleihan, Maria Luisa Brandi, René Rizzoli, Cyrille B Confavreux

{"title":"Bone Effects of Anti-Cancer Treatments in 2024.","authors":"Marie Teissonnière, Mathieu Point, Emmanuel Biver, Peyman Hadji, Edith Bonnelye, Peter R Ebeling, David Kendler, Tobias de Villiers, Gerold Holzer, Jean-Jacques Body, Ghada El Hajj Fuleihan, Maria Luisa Brandi, René Rizzoli, Cyrille B Confavreux","doi":"10.1007/s00223-025-01362-0","DOIUrl":null,"url":null,"abstract":"<p><p>Considerable progress has been made in the management of cancer patients in the last decade with the arrival of anti-cancer immunotherapies (immune checkpoint inhibitors) and targeted therapies. As a result, a broad spectrum of cancers, not just hormone-sensitive ones, have seen several patients achieve profound and prolonged remissions, or even cures. The management of medium- and long-term side-effects of treatment and quality of life of patients are essential considerations. This is especially true for bone, as bone fragility can lead to increased fractures and loss of autonomy, ultimately reducing the possibility of resuming physical activity. Physical activity is essential for lasting oncological remission and prevention of fatigue. While the issue of hormone therapies and their association with breast cancer has been recognized for some time, the situation is relatively new with regards to targeted therapies and immunotherapies. This is particularly challenging given the wide range of available targeted therapies and their application to numerous cancer types. This article provides a comprehensive review of the bone effects of the main anti-cancer therapies currently in use. The review goes beyond glucocorticoids and hormone therapies and discusses for each drug category what is known regarding cellular effects, BMD effects, and fracture incidence.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"116 1","pages":"54"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950069/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Calcified Tissue International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00223-025-01362-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Considerable progress has been made in the management of cancer patients in the last decade with the arrival of anti-cancer immunotherapies (immune checkpoint inhibitors) and targeted therapies. As a result, a broad spectrum of cancers, not just hormone-sensitive ones, have seen several patients achieve profound and prolonged remissions, or even cures. The management of medium- and long-term side-effects of treatment and quality of life of patients are essential considerations. This is especially true for bone, as bone fragility can lead to increased fractures and loss of autonomy, ultimately reducing the possibility of resuming physical activity. Physical activity is essential for lasting oncological remission and prevention of fatigue. While the issue of hormone therapies and their association with breast cancer has been recognized for some time, the situation is relatively new with regards to targeted therapies and immunotherapies. This is particularly challenging given the wide range of available targeted therapies and their application to numerous cancer types. This article provides a comprehensive review of the bone effects of the main anti-cancer therapies currently in use. The review goes beyond glucocorticoids and hormone therapies and discusses for each drug category what is known regarding cellular effects, BMD effects, and fracture incidence.

查看原文本刊更多论文

2024年抗癌治疗的骨效应。

在过去的十年中，随着抗癌免疫疗法（免疫检查点抑制剂）和靶向治疗的出现，癌症患者的管理取得了相当大的进展。因此，不仅是激素敏感型癌症，很多癌症患者的病情都得到了长期的缓解，甚至得到了治愈。治疗的中期和长期副作用的管理和患者的生活质量是必不可少的考虑因素。对于骨骼来说尤其如此，因为骨骼脆弱会导致骨折增加和自主性丧失，最终降低恢复体力活动的可能性。体育活动对于持久的肿瘤缓解和预防疲劳是必不可少的。虽然激素疗法的问题及其与乳腺癌的关系已经被认识了一段时间，但在靶向治疗和免疫治疗方面，情况相对较新。这尤其具有挑战性，因为现有的靶向治疗方法范围广泛，而且它们适用于许多癌症类型。本文综述了目前常用的主要抗癌疗法对骨的影响。这篇综述超越了糖皮质激素和激素治疗，并讨论了每种药物在细胞效应、骨密度效应和骨折发生率方面的已知情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Calcified Tissue International 医学-内分泌学与代谢

CiteScore

8.00

自引率

2.40%

发文量

112

审稿时长

4-8 weeks

期刊介绍： Calcified Tissue International and Musculoskeletal Research publishes original research and reviews concerning the structure and function of bone, and other musculoskeletal tissues in living organisms and clinical studies of musculoskeletal disease. It includes studies of cell biology, molecular biology, intracellular signalling, and physiology, as well as research into the hormones, cytokines and other mediators that influence the musculoskeletal system. The journal also publishes clinical studies of relevance to bone disease, mineral metabolism, muscle function, and musculoskeletal interactions.